10x Genomics Analyst Price Targets

Wall Street analyst price targets and consensus rating for 10x Genomics (TXG).

Price Target Range — 12 Quarters

Analyst Consensus — 18 Analysts

7Buy

10Hold

1Sell

Consensus RatingNeutral# Analysts18Avg. Consensus PT$46Upside to Avg. PT-47.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	Leerink Partners	Mike Kratky	PT Raise	Market Perform	$40→$90
Sep 28, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$47→$80
Sep 28, 2026	Argus Research	John Eade	Initiate	Buy	$110
Sep 9, 2026	UBS	Dan Leonard	PT Raise	Neutral	$20→$68
Sep 1, 2026	RBC Capital	Dan Leonard	Initiate	Sector Perform	$70
Aug 12, 2026	Stephens & Co.	Mason Carrico	PT Raise	Overweight	$50→$65
Aug 10, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$42→$47
Aug 10, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$50→$60
Aug 7, 2026	Citigroup	Brendan Digan	PT Raise	Neutral	$45→$50
Aug 7, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$37→$40
Jul 17, 2026	Leerink Partners	Mike Kratky	PT Raise	Market Perform	$23→$40
Jul 14, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$32→$50
Jul 9, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$22→$37
Jul 8, 2026	Citigroup	Patrick Donnelly	PT Raise	Neutral	$24→$45
Jul 1, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$20→$42
Jun 24, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$30→$40
May 12, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$20→$22
May 12, 2026	JP Morgan	Casey Woodring	PT Raise	Neutral	$17→$20
Apr 20, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$22→$32
Apr 20, 2026	B of A Securities	Derik De Bruin	PT Raise	Neutral	$21→$30

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

Leerink Partners analyst Mike Kratky maintains 10x Genomics (NASDAQ:TXG) with a Market Perform and raises the price target from $40 to $90.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $47 to $80.

Benzinga Newsdesk

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).

Avi Kapoor

PRO
Argus Research Initiates Coverage On 10x Genomics with Buy Rating, Announces Price Target of $110

Argus Research analyst John Eade initiates coverage on 10x Genomics (NASDAQ:TXG) with a Buy rating and announces Price Target of $110.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on 10x Genomics, Raises Price Target to $68

UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $68.

Benzinga Newsdesk

PRO
RBC Capital Initiates Coverage On 10x Genomics with Sector Perform Rating, Announces Price Target of $70

RBC Capital analyst Dan Leonard initiates coverage on 10x Genomics (NASDAQ:TXG) with a Sector Perform rating and announces Price Target of $70.

Benzinga Newsdesk

10x Genomics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

10x Genomics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

PRO
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PRO
Argus Research Initiates Coverage On 10x Genomics with Buy Rating, Announces Price Target of $110

PRO
UBS Maintains Neutral on 10x Genomics, Raises Price Target to $68

PRO
RBC Capital Initiates Coverage On 10x Genomics with Sector Perform Rating, Announces Price Target of $70

People Also Watch

People Also Watch

10x Genomics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

10x Genomics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

PROPiper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PROArgus Research Initiates Coverage On 10x Genomics with Buy Rating, Announces Price Target of $110

PROUBS Maintains Neutral on 10x Genomics, Raises Price Target to $68

PRORBC Capital Initiates Coverage On 10x Genomics with Sector Perform Rating, Announces Price Target of $70

People Also Watch

People Also Watch

PRO
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

PRO
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80

PRO
Argus Research Initiates Coverage On 10x Genomics with Buy Rating, Announces Price Target of $110

PRO
UBS Maintains Neutral on 10x Genomics, Raises Price Target to $68

PRO
RBC Capital Initiates Coverage On 10x Genomics with Sector Perform Rating, Announces Price Target of $70